New combo could tame dangerous side effect of popular diabetes drug
NCT ID NCT07056699
Summary
This study aims to see if adding the drug pioglitazone can block some risky side effects of the diabetes drug dapagliflozin in people with Type 1 diabetes. Dapagliflozin helps lower blood sugar but can increase fat breakdown and ketone production, raising the risk of a dangerous condition called ketoacidosis. Researchers will enroll 24 adults with Type 1 diabetes to test if the pioglitazone combination reduces these risks while still helping control blood sugar.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute
San Antonio, Texas, 78229-3900, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.